Changes in the management of chronic thromboembolic pulmonary hypertension over a 10-year period, in a French expert regional competence centre

Status and Future Directions for Balloon Pulmonary Angioplasty in Chronic Thromboembolic Pulmonary Disease With and Without Pulmonary Hypertension: A Scientific Statement From the American Heart Association

“…8,9 More recently, percutaneous revascularization of pulmonary vascular obstructions with balloon pulmonary angioplasty (BPA) has emerged as a potential treatment option for individuals who are unsuitable candidates for PEA or have residual obstruction after PEA. [10][11][12][13] Although BPA has the potential to positively affect many patients, proper promulgation of this therapy accounting for the risk-benefit profile of the procedure for individual patients has yet to be formally addressed by any group of experts. Adoption of BPA to date has been driven primarily by personal peer-to-peer contact and training.…”

“…8,9 More recently, percutaneous revascularization of pulmonary vascular obstructions with balloon pulmonary angioplasty (BPA) has emerged as a potential treatment option for individuals who are unsuitable candidates for PEA or have residual obstruction after PEA. 10–13…”